| Effect of food on the relative bioavailability of a hypolipidemic agent (CGP 43371) in healthy subjects. | |
| | |
MedLine Citation:
|
PMID: 8169802 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
The relative bioavailability of a capsule formulation and the effects of food on the pharmacokinetics of a hypolipidemic agent (CGP 43371) in 12 healthy subjects were examined. Each subject randomly received a single dose of 800 mg of CGP 43371, either as a dispersion formulation under fasting conditions or as a capsule formulation under fasting and fed conditions in a three-way crossover design with a washout period of 2 weeks between each treatment. Serial blood samples were collected at frequent intervals up to 96 h after each treatment. The concentrations of CGP 43371 in plasma were determined by a normal-phase HPLC method. Similar mean pharmacokinetic data (peak plasma drug concentration, 0.16 versus 0.18 micrograms/mL; area under the plasma drug concentration-time curve from time zero to infinity, 4.56 versus 4.22 micrograms.h/mL; time to the peak plasma drug concentration, 10.3 versus 10.2 h; lag time, 3.7 versus 3.8 h; and terminal elimination half-life, 17.8 versus 15.0 h) for the dispersion and capsule formulations under fasting conditions indicated that both formulations were bioequivalent with respect to the rate and extent of absorption. In contrast, the mean peak plasma drug concentration (2.01 micrograms/mL) and area under the curve from time zero to infinity (57.35 micrograms.h/mL) for the capsule formulation with food were enhanced approximately 11- and 14-fold, respectively, when compared with that without food. The corresponding mean lag time (2.1 h) was decreased approximately 50%. These differences in pharmacokinetic parameters were statistically significant, on the basis of an analysis of variance.(ABSTRACT TRUNCATED AT 250 WORDS) |
| | |
Authors:
|
J X Sun; A Cipriano; K Chan; M Klibaner; V A John |
Publication Detail:
|
Type: Clinical Trial; Journal Article; Randomized Controlled Trial |
Journal Detail:
|
Title: Journal of pharmaceutical sciences Volume: 83 ISSN: 0022-3549 ISO Abbreviation: J Pharm Sci Publication Date: 1994 Feb |
Date Detail:
|
Created Date: 1994-06-01 Completed Date: 1994-06-01 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 2985195R Medline TA: J Pharm Sci Country: UNITED STATES |
Other Details:
|
Languages: eng Pagination: 264-6 Citation Subset: IM |
Affiliation:
|
Drug Development Department, CIBA-GEIGY Corp., Ardsley, NY 10502. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Anticholesteremic Agents
/
adverse effects,
pharmacokinetics* Biological Availability Capsules Chromatography, High Pressure Liquid Emulsions Food* Half-Life Humans Intestinal Absorption Male Rifampin / adverse effects, analogs & derivatives*, pharmacokinetics |
| Chemical | |
Reg. No./Substance:
|
0/Anticholesteremic Agents; 0/Capsules; 0/Emulsions; 123036-23-7/CGP 43371; 13292-46-1/Rifampin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A novel skeletal drug-delivery system using self-setting calcium phosphate cement. 4. Effects of the...
Next Document: Objective diagnosis of equinus during gait prior to and following a tibial nerve block.